Ulcerative Colitis

...Currently, there are no biologic therapies approved to treat moderately to severely active UC in the European Union (EU), hence patients have limited treatment options."The CHMP’s positive opinion represents a milestone in the treatment of Spiegel, M.D., chief medical officer and senior vice president of medical affairs, Schering-Plough Research Institute.

"In the pivotal clinical studies, patients receiving REMICADE achieved high rates of clinical response and clinical remission as well as mucosal healing and reduced rates of hospitalization.

These are excellent results for this patient population that had failed available therapeutic options."The CHMP recommendation is an important step towards a European Commission approval.

A Commission approval of the application will result in Marketing Authorization with unified labeling that will be valid in all EU-member states, including the current 25 member states as well as Iceland and Norway.The positive opinion for REMICADE for UC is based on data from the ACT 1 and ACT 2 clinical trials.

ACT 1 and ACT 2 were multicenter, Phase 3, randomized, double-blind, placebo-controlled, clinical trials conducted to evaluate ...

...Currently, there are no biologic therapies approved to treat moderately to severely active UC in the European Union (EU), hence patients have limited treatment options.

"The CHMP's positive opinion represents a milestone in the treatment of Spiegel, M.D., chief medical officer and senior vice president of medical affairs, Schering-Plough Research Institute.

"In the pivotal clinical studies, patients receiving REMICADE achieved high rates of clinical response and clinical remission as well as mucosal healing and reduced rates of hospitalization.

These are excellent results for this patient population that had failed available therapeutic options." The CHMP recommendation is an important step towards a European Commission approval.

A Commission approval of the application will result in Marketing Authorization with unified labeling that will be valid in all EU-member states, including the current 25 member states as well as Iceland and Norway.

The positive opinion for REMICADE for UC is based on data from the ACT 1 and ACT 2 clinical trials.

ACT 1 and ACT 2 were multicenter, Phase 3, randomized, double-blind, placebo-controlled, clinical trials conducted to evaluate the ...

... European Union CHMP Recommends Approval of REMICADE (R) for Treatmen..

                        European Union CHMP Recommends Approval of REMICADE (R) for Treatmen..

U hebt een pagina opgevraagd uit de Nieuwsbank persberichtendatabank.

Nieuwsbank levert deze pagina alleen gratis aan haar abonnees.

Klik hier om uw wachtwoord op te geven als u reeds abonnee bent.

Of hier om snel abonnee te worden.

Wilt u alleen gratis berichten zien, gebruik dan deze lijst.

Voor niet-abonnees is deze pagina tegen een vergoeding van EUR 5,00 (Teletik abonnees 1 euro) te bezichtigen.

Vul daartoe onderstaand formulier in en klik op "betalen".

Lees eerst dit: (klik hier om direct naar het formulier te gaan) Uw email-adres blijft vertrouwelijk.

Plaats eerst een boekenlegger op deze link voordat u op 'betalen' klikt.

Dat gaat als volgt: wijs met uw muis naar het woord 'link' en klik rechts.

In het menuutje klikt u 'Toevoegen aan Favorieten' of 'Add Bookmark'.

Via uw Favorieten of Bookmarks menu vindt u dit bericht dan later altijd weer terug.

Ook als u geen factuur wilt, vul dan bij persoonsgegevens ...